本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 一、前次资产抵押担保及解除情况 近日公司已根据相关协议要求配合抵押权人片仔癀办理了相应房产的抵押登记手续。上述资产抵押不会 对公司生产经营产生影响。敬请投资者注意风险，理性投资。 特此公告。 狮头科技发展股份有限公司董事会 2025年7月23日 杭州创化已于2024年12月24日全部结清上述抵押合同项下所担保的账期，抵押权人片仔癀于2025年6月 23日办理了上述资产抵押解除手续，登记部门依法办理完毕抵押权注销登记。 二、本次资产抵押担保的情况 公司于2025年6月17日召开第九届董事会第二十一次会议，审议通过了《关于为控股子公司提供抵押担 保的议案》，同意公司为杭州创化与片仔癀签订的2025年度片仔癀化妆品经销合同书所约定的账期以自 有房产提供抵押担保，担保最高额度为800万元。抵押物为公司名下位于山西省太原市滨河西路51号3幢 1-2层0201号非住宅房地产。杭州创化及其股东昆汀科技为公司的上述抵押担保提供反担保。2025年6月 17日，公司与片仔癀签署了《最高额抵押合 ...

Core Viewpoint - The innovative drug market is experiencing a surge in interest and investment, with significant inflows of capital and strong performance in related stocks [1][5]. Group 1: Market Performance - On July 15, the pharmaceutical ETF (562050) experienced a sharp increase during the opening auction, indicating heightened investor enthusiasm for innovative drugs [2][3]. - The ETF closed up 0.59% at 1.017 yuan per share, with a total trading volume of approximately 26.34 million yuan and a turnover rate of 22.94% [4]. - A-shares in innovative drugs have shown notable gains, with companies like ShenZhou Cell rising nearly 50% in the past month, and others like BoRui Medicine and Jilin AoDong increasing over 10% [5]. Group 2: Fund Performance and Strategy - The latest public fund reports reveal a significant shift towards innovative drugs, with the Changcheng Pharmaceutical Industry Selected Fund achieving over 90% returns, increasing its scale nearly 30 times in the second quarter [6][9]. - The fund manager of Yongying Medical Health Fund indicated a complete portfolio overhaul towards innovative drugs, with top holdings including ShuTaiShen and Rejing Biology, the latter seeing a staggering 443.59% increase this year [6][7]. - The Changcheng fund plans to continue focusing on innovative drugs in the third quarter, emphasizing clinical data, overseas licensing, and domestic sales growth [8]. Group 3: Policy and Market Trends - The innovative drug sector is benefiting from favorable policy developments, with the National Medical Insurance Bureau initiating adjustments to the drug catalog for 2025 [10]. - Data shows that the total amount for Chinese innovative drug licenses reached nearly 66 billion USD in the first half of 2025, surpassing the total for 2024, indicating a rapid rise in global competitiveness [11]. - The current market rally is primarily driven by clinical results and expectations for overseas licensing, with a focus on companies that have the potential for international expansion and those that have successfully transformed [11].

Core Viewpoint - The article emphasizes the importance of early eye care and highlights a specific eye cream, the "Huanghou Brand Jingyan Huancai Eye Cream," which is praised for its effectiveness and affordability [10][20][63]. Group 1: Product Effectiveness - The eye cream claims to address multiple issues such as wrinkles, dark circles, and skin tightening, making it a comprehensive solution for eye care [24][25]. - Ingredients like white pool flower seed oil and niacinamide are noted for their moisturizing and skin-brightening properties, significantly improving hydration levels [27][38][35]. - User testimonials and testing results indicate that the product effectively reduces wrinkles and improves skin tightness, with many users reporting visible improvements [45][50][47]. Group 2: Market Position and Pricing - The eye cream is positioned as a high-quality yet affordable option, originally priced at 138 yuan but currently available for 69 yuan, with further discounts for bulk purchases [20][66]. - The brand has a strong reputation, having been in the market for 43 years with minimal negative feedback, relying on word-of-mouth for its marketing [63][64]. - The product has garnered significant attention, with over 50,000 positive reviews on its flagship store, indicating strong consumer satisfaction [15][10][63].

近日，中国工程院院刊主刊《Engineering》通过其公众号平台发布的文章显示，香港中文大学于君教授 团队的一项研究首次证明了"片仔癀可能是预防和治疗脂肪肝炎的有效药物"。 于君教授团队的研究通过小鼠实验，评估了片仔癀在NASH防治中的作用及潜在机制，其研究结果显 示，片仔癀能有效预防由多种饮食[包括高脂高胆固醇饮食（HFHC）、胆碱缺乏的高脂饮食（CD- HFD）以及蛋氨酸胆碱缺乏饮食（MCD）]引起的NASH进展，同时显著抑制肝损伤、肝脏甘油三酯聚 集和脂质过氧化。从机制上讲，小鼠实验结果显示片仔癀是通过调节肠道菌群，恢复肠道屏障，改变肠 道代谢物的功能，从而通过肠-肝轴缓解NASH的发生和进展。 《中国脂肪肝防治指南》数据显示，近年来我国脂肪肝发病率逐年升高，其中成人脂肪肝患病率已经达 到12.5%～35.4% ，平均每3个人里就有1人罹患脂肪肝。申万宏源相关研究指出，随着肥胖、2型糖尿病 和代谢综合征的流行，NAFLD已成为包括我国在内的全球第一大肝脏疾病。可以说，于君教授团队开 展的片仔癀防治脂肪肝研究为中国第一大肝病防治提供了一条新思路。 实际上，片仔癀(600436)这些年在中药二次开发方面的 ...

Group 1 - The medical health ETF Taikang (159760) has seen a 0.17% increase, marking its fifth consecutive rise, while the index it tracks, the National Certificate Public Health and Medical Health Index (980016), rose by 0.13% [1] - As of July 14, the latest scale of the medical health ETF Taikang reached 82.4979 million yuan, a new high in nearly three months [2] - The medical device sector is expected to experience a performance turning point, driven by policies such as the old-for-new program and the gradual clearance of channel inventory [2] Group 2 - The top ten weighted stocks in the National Certificate Public Health and Medical Health Index account for 51.67% of the index, with leading companies including WuXi AppTec (603259) and Hengrui Medicine (600276) [3] - The CDMO sector has rebounded, with WuXi AppTec expected to see significant growth in revenue and profit by mid-2025, indicating strong global market demand [2] - The innovation drug industry chain is anticipated to enter a new upward cycle, supported by an improving domestic investment environment and active financing activities [2]

Investment Rating - The industry maintains an "Overweight" rating, suggesting a positive outlook for investment opportunities in the Chinese medicine sector [6]. Core Insights - The Chinese medicine sector saw a 1.08% increase last week, with the overall pharmaceutical sector experiencing a general upward trend [2]. - The price-to-earnings (PE) ratio for the Chinese medicine sector is 27.86X, reflecting a slight increase, while the price-to-book (PB) ratio stands at 2.31X, also showing a minor rise [3]. - The market for Chinese medicinal materials is currently in a low season, with a slight decline in price indices due to increased rainfall in southern regions [4]. - As of July 12, 2025, three out of five listed companies in the Chinese medicine industry reported positive net profit growth, with the lowest growth rate at 24.3% [5]. Summary by Sections Market Performance - The Chinese medicine sector index closed at 6451.72 points, up 1.08% last week, while the overall pharmaceutical index rose by 1.82% [2][17]. Valuation - The PE ratio (ttm) for the Chinese medicine sector is 27.86X, up 0.29X week-on-week, with a one-year maximum of 30.13X and a minimum of 22.58X. The PB ratio (lf) is 2.31X, up 0.03X, with a one-year maximum of 2.65X and a minimum of 1.99X [3][19]. Industry Trends - The Chinese medicine sector is entering the mid-year reporting season, with a focus on performance metrics such as inventory and accounts receivable [5]. - The report highlights three main investment themes: price governance, consumption recovery, and state-owned enterprise reform, indicating potential growth areas within the sector [6][9]. Investment Recommendations - Recommended companies include those with strong R&D capabilities and unique products, as well as those less affected by price collection policies. Specific companies highlighted are Zhaoli Pharmaceutical, Pizaihuang, and Shouxiangu [10].

金融界7月9日消息，A股三大指数收盘涨跌不一，沪深300制药指数(300制药，L11640)报11609.22点。 数据统计显示，沪深300制药指数近一个月下跌2.48%，近三个月上涨5.29%，年至今上涨6.57%。 据了解，沪深300制药指数从沪深300指数中选取与制药主题相对应的行业内上市公司证券作为指数样 本，以反映该主题上市公司证券的整体表现。该指数以2004年12月31日为基日，以1000.0点为基点。 从指数持仓来看，沪深300制药指数十大权重分别为：恒瑞医药（41.61%）、片仔癀（10.46%）、云南 白药（8.71%）、科伦药业（6.52%）、华东医药（6.0%）、新和成（5.88%）、复星医药（5.59%）、 同仁堂（4.26%）、百利天恒（4.09%）、华润三九（3.63%）。 从沪深300制药指数持仓的市场板块来看，上海证券交易所占比69.26%、深圳证券交易所占比30.74%。 从沪深300制药指数持仓样本的行业来看，药品制剂占比63.81%、中成药占比30.31%、原料药占比 5.88%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下 ...

7月7日，片仔癀连续8个交易日下跌，区间累计跌幅-2.33%。漳州片仔癀药业股份有限公司是以医药制 造为主业的中华老字号企业,由成立于1956年的漳州制药厂在1999年改制创立,于2003年在上交所上市,现 股本6.03亿。 易方达沪深300医药ETF基金经理为余海燕。 财报显示，易方达基金旗下易方达沪深300医药ETF为片仔癀前十大股东，今年一季度减持。今年以来 收益率1.83%，同类排名2076(总3422)。 | 阶段涨幅 | 季度涨幅 年度涨幅 | | | | | | --- | --- | --- | --- | --- | --- | | | 近1周 | 近1月 | 近3月 | 近6月 | 今年来 | | 阶段涨幅 | -0.35% | -1.71% | 6.69% | 6.60% | 1.83% | | 同类平均6 | 1.05% | 3.38% | 3.45% | 10.12% | 5.48% | | 沪深300 | 0.74% | 2.35% | 10.47% | 4.45% | 0.77% | | 跟踪标的� | -0.42% | -1.92% | 5.85% | 5.85% | 1.13 ...

Investment Rating - The industry rating is maintained at "Overweight" [6] Core Insights - The Chinese medicine sector saw a 1.27% increase last week, lagging behind other pharmaceutical segments, with the overall pharmaceutical sector rising by 3.64% [2] - The price-to-earnings (PE) ratio for the Chinese medicine sector is 27.57X, up 0.34X week-on-week, while the price-to-book (PB) ratio is 2.28X, also showing a slight increase [3] - The market for traditional Chinese medicine materials is experiencing increased supply but declining prices, with a 0.5% drop in the total price index last week [4] Summary by Sections Market Performance - The Chinese medicine sector's performance is weaker compared to other pharmaceutical segments, with notable companies like Jiuzi Tang and Zoli Pharmaceutical performing well, while others like Mayinglong and Dong'e Ejiao lag behind [2][15] Valuation - The current PE ratio of 27.57X places the sector at the 29.53% percentile since 2013, while the PB ratio of 2.28X is at the 5.37% percentile [3] Supply Chain Dynamics - The market for Chinese medicinal materials is characterized by increased production and declining prices, with a significant number of categories experiencing price drops [4] Policy Developments - The dual-track system for medical insurance and commercial insurance is being implemented, allowing for dynamic adjustments and submissions for inclusion in the basic medical insurance directory [5][6] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform, highlighting companies with strong R&D capabilities and unique products [11][12][13]

Group 1 - The equity change will not alter the controlling shareholder or actual controller of Zhangzhou Pianzaihuang Pharmaceutical Co., Ltd. [2][5] - After the equity change, Zhangzhou Jiulongjiang Group Co., Ltd. will still hold 307,522,643 shares, accounting for 50.97% of the total share capital of the company [2][4] - Fujian Zhanglong Group Co., Ltd. has committed not to reduce the shares obtained from the free transfer for 36 months after the completion of the share transfer registration [2][5] Group 2 - The basic situation of the state-owned share free transfer indicates that Jiulongjiang Group plans to transfer 2,000,000 shares (0.33% of the total share capital) to Zhanglong Group [2] - The free transfer of state-owned shares has been approved by the State-owned Assets Supervision and Administration Commission of Zhangzhou City [2] - The share transfer registration has been confirmed by China Securities Depository and Clearing Corporation Limited [3] Group 3 - After the completion of the free transfer, Jiulongjiang Group will directly hold 307,522,643 unrestricted shares, accounting for 50.97% of the total share capital, while Zhanglong Group will hold 7,056,700 unrestricted shares, accounting for 1.17% [4]